FCCC LOGO Faculty Publications
Fanale MA , Horwitz SM , Forero-Torres A , Bartlett NL , Advani RH , Pro B , Chen RW , Davies A , Illidge T , Uttarwar M , Lee SY , Ren H , Kennedy DA , Shustov AR
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Blood. 2018 May;131(19) :2120-2124
PMID: 29507077    PMCID: PMC5946765    URL: https://www.ncbi.nlm.nih.gov/pubmed/29507077
Back to previous list
Abstract
This phase 1 study evaluated frontline brentuximab vedotin in combination with cyclophos-phamide, doxorubicin, and prednisone (BV+CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy) in 26 patients with CD30(+) peripheral T-cell lymphoma, including 19 with systemic anaplastic large cell lymphoma. All patients (100%) achieved an objective response, with a complete remission (CR) rate of 92%; none received a consolidative stem cell transplant. After a median observation period of 59.6 months (range, 4.6-66.0) from first dose, neither the median progression-free survival (PFS) nor the median overall survival (OS) was reached. No progression or death was observed beyond 35 months. The estimated 5-year PFS and OS rates were 52% and 80%, respectively. Eighteen of 19 patients (95%) with treatment-emergent peripheral neuropathy (PN) reported resolution or improvement of symptoms. Thirteen patients (50%) remained in remission at the end of the study, with PFS ranging from 37.8+ to 66.0+ months. Eight of these 13 patients received the maximum 16 cycles of study treatment. These final results demonstrate durable remissions in 50% of patients treated with frontline BV+CHP, suggesting a potentially curative treatment option for some patients.
Notes
Fanale, Michelle A. Horwitz, Steven M. Forero-Torres, Andres Bartlett, Nancy L. Advani, Ranjana H. Pro, Barbara Chen, Robert W. Davies, Andrew Illidge, Tim Uttarwar, Mayur Lee, Shih-Yuan Ren, Hong Kennedy, Dana A. Shustov, Andrei R. 1528-0020